TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02057627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal Dyadic Psychotherapy
Description: 8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Standard care plus depression monitoring by phone
Study: NCT01091337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procaterol
Description: Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes~+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
Study: NCT03832075

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Description: Berg Balance Scale is 14 item scale for detecting balance disorder.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Timed Up and Go Test
Description: Timed Up and Go Test assesses mobility, balance, walking ability, and fall risk in older adults.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Korebalance Balance System
Description: Korebalance Balance System evaluates the balance and stability using objective neuro-sensory balance assessment. Static Test requires standing steady \& balancing on the platform, keeping the crosshairs of cursor in the center of the test pattern. The Score indicates the deviation of user's center of gravity from the center of the pattern. Dynamic Test offers a moving cursor that the user follows. Four patterns are offered: Circle, Square, Infinity and Random. Each pattern is available in three dimensions: Small, Medium and Large; five speeds; Clockwise and Counterclockwise directions.
Study: NCT02072239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioshield
Description: The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
Study: NCT03144024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: band implantation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rigid ring implantation
Study: NCT03300518

Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin Beta;MSD
Description: Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.

Intervention type: DRUG
Group type: OTHER
Intervention: Follitropin Beta;MSD
Description: Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.

Intervention type: DRUG
Group type: OTHER
Intervention: Ganirelix
Description: A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.

Intervention type: DRUG
Group type: OTHER
Intervention: Ganirelix
Description: A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
Study: NCT00940121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: IV solution
Study: NCT03300518

Intervention type: DRUG
Group type: OTHER
Intervention: hCG
Description: Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger

Intervention type: DRUG
Group type: OTHER
Intervention: hCG
Description: Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger

Intervention type: DRUG
Group type: OTHER
Intervention: estradiol valerate
Description: Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
Study: NCT01054807

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A Habitual Lens
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A Habitual Lens
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A Habitual Lens
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A Habitual Lens
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A Habitual Lens
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A Habitual Lens
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.7 BC (Investigational)
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.7 BC (Investigational)
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.7 BC (Investigational)
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.7 BC (Investigational)
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.7 BC (Investigational)
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.7 BC (Investigational)
Description: Comparison of three soft contact lens designs.

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.3 BC (Investigational)
Description: Comparison of three soft contact lens designs

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.3 BC (Investigational)
Description: Comparison of three soft contact lens designs

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.3 BC (Investigational)
Description: Comparison of three soft contact lens designs

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.3 BC (Investigational)
Description: Comparison of three soft contact lens designs

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.3 BC (Investigational)
Description: Comparison of three soft contact lens designs

Intervention type: DEVICE
Group type: OTHER
Intervention: Galyfilcon A 8.3 BC (Investigational)
Description: Comparison of three soft contact lens designs
Study: NCT03913325

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PREVSAM model
Description: A person-centred rehabilitation plan, including coordinated measures within primary health care as well as in collaboration with participants' employers, and when relevant the Swedish Public Employment Agency
Study: NCT05706662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inguinal hernia repair with mesh
Description: inguinal hernia repair with mesh

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inguinal hernia repair with mesh
Description: inguinal hernia repair with mesh
Study: NCT03913325

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (standard treatment)
Description: Treatment as usual (ordinary/standard) treatment. Can include unimodal or multimodal treatment of physiotherapy solely and/or occupational therapy
Study: NCT01462786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: 2 mg/cm2 ATX-101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: 2 mg/cm2 ATX-101
Study: NCT01181648

Intervention type: BEHAVIORAL
Intervention: questionnaire and semi-structured interviews
Description: Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
Study: NCT05294536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection,RD12014
Description: single dose, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection,RD12014
Description: single dose, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection,Victoza
Description: single dose, s.c. injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide injection,Victoza
Description: single dose, s.c. injection
Study: NCT04295655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Exercise intervention
Description: The program included 15 minutes of deep breathing exercises and 20-30 minutes of limb exercises. The exercises included global active range of motion (ROM) exercises and muscle strengthening like upper and lower limbs flexion-extension do single-leg stance, and sit to stand exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrostimulation Group
Description: The program included a neuromuscular stimulation therapy on quadriceps accompanied by lower limb exercises. The intervention was performed following the protocol described by Valenza et al (2017).~Valenza MC, Torres-Sánchez I, López-López L, Cabrera-Martos I, Ortiz-Rubio A, Valenza-Demet G. Effects of home-based neuromuscular electrical stimulation in severe chronic obstructive pulmonary disease patients: a randomized controlled clinical trial. Eur J Phys Rehabil Med. 2018 Jun;54(3):323-332. doi: 10.23736/S1973-9087.17.04745-1. Epub 2017 Nov 16. PubMed PMID: 29144103.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Patients received standard medical and pharmacological care that consisted in systemic steroids, inhaled bronchodilators, oxygen, and a regimen of oral prednisone or its equivalent in doses of 40 to 60 mg per day for the duration of therapy as well as anti-biotic therapy
Study: NCT02826135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominal compression
Description: When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output or decreased central venous pressure, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
Study: NCT02961218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Description: Monthly doses of 4 mg/kg for subjects weighing ≤40 kg and 300 mg for all other subjects

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly doses of placebo to match the administered dose of canakinumab s.c.
Study: NCT01331941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 + Paclitaxel
Description: 15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m\^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 + Paclitaxel
Description: 15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m\^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 + Paclitaxel
Description: 15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m\^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
Study: NCT00940121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: IV solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: IV solution
Study: NCT02393690

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I-131
Description: Given PO

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Iodine I-131
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study: NCT05561257

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C
Study: NCT02934633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keeping Baby Safe 2-DVD package
Description: Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Injury Prevention Program (TIPP) sheets
Description: American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
Study: NCT03609749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training for Primary Care
Description: For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home (Phase 3)
Study: NCT03519438

Intervention type: OTHER
Intervention: Mepitel
Description: Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis

Intervention type: OTHER
Intervention: Mepitel
Description: Mepitel film will be placed on 3/4 of treatment field to protect from radiation dermatitis
Study: NCT03944057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-010
Description: ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle).~Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)
Study: NCT01523236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: 50 mcg/actuation Nasal Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasonex®
Description: 50 mcg/actuation Nasal Spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Spray
Study: NCT01424098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training program
Description: Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
Study: NCT00869713

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Inactivated, Dried (TSI-GSD 200), RVF Vaccine
Description: All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 \& 14, \& once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer \<1:40. Initial non-responders: Individual who has a PRNT80 titer \<1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 \<1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of \<1:40.
Study: NCT02647853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAT4 Gel concentration A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAT4 Gel concentration B

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00686179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Capsule, oral, single dose, 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3480
Description: Capsule, oral, single dose, 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Capsule(encapsulated), oral, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Capsule, oral, single dose
Study: NCT01954732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02526836

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional Surgery
Description: removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete mesocolic excision with central vascular ligation
Description: excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
Study: NCT03200665

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound 35-36 (6 / 7 days weeks)
Description: An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
Study: NCT04121416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone 10mg
Description: induction with 0.3mg/kg of oxycodone in general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: induction with 0.3 µg/kg of Sufentanil in general anesthesia
Study: NCT00620464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiopaque Implanon
Description: Radiopaque rod for 3 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Implanon (etonogestrel implant)
Description: Implanon (etonogestrel implant) for 3 years
Study: NCT03324672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TRIGGER
Description: only TRIGGER point will be included for the manual therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TRIGGER+CURETAPE
Description: TRIGGER point will be included for the manual therapy with kinesio-taping
Study: NCT01387373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, capecitabine, trastuzumab
Description: Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
Study: NCT05357196

Intervention type: DRUG
Group type: OTHER
Intervention: PT-112
Description: Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg.
Study: NCT04526301

Intervention type: DEVICE
Intervention: Tablo Hemodialysis System
Description: Home hemodialysis treatments \~4 times a week.
Study: NCT02207985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Study: NCT01119560

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Correlative studies

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01352468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multifaceted cognitive training
Description: Four computerized training tasks
Study: NCT03123640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication reconciliation and medication review
Description: Pharmacist performed medication reconciliation and medication review
Study: NCT02763631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Treatment
Description: Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Run In Phase
Description: Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Stand Care Arm
Description: No change will be made to participants care